Aquestive Therapeutics (AQST) Liabilities and Shareholders Equity (2017 - 2026)

Aquestive Therapeutics' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $141.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 38.04% year-over-year to $141.1 million; the TTM figure through Mar 2026 stood at $558.8 million (up 29.59% YoY), while the FY2025 annual figure was $160.4 million, up 58.17% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $141.1 million, down from $160.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $163.6 million in Q3 2025, with the low at $51.8 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $93.7 million (2025), against an average of $92.7 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 111.35% in 2024, then slipped 21.07% in 2025.
• Aquestive Therapeutics' Liabilities and Shareholders Equity stood at $57.1 million in 2022, then gained by 0.61% to $57.4 million in 2023, then surged by 76.64% to $101.4 million in 2024, then surged by 58.17% to $160.4 million in 2025, then decreased by 12.03% to $141.1 million in 2026.
• Business Quant data shows AQST's Liabilities and Shareholders Equity at $141.1 million in Q1 2026, $160.4 million in Q4 2025, and $163.6 million in Q3 2025.